Madeline R. Spetz

Keywords neuroblastoma glypican-2 GPC2 monoclonal antibody antibody humanization gamma/delta TCR antibody-TCR AbTCR chimeric antigen receptor CAR cell therapy CD30 Introduction Neuroblastoma is the second most frequently occurring extracranial solid tumor in children, accounting for 8%–10% of all pediatric cancers and 15% of cancer-related deaths in children.1 A major challenge in treating many cancers, including neuroblastoma, is the lack of effective therapeutic targets.

Highlights RNA-seq analysis identifies tumor-associated exons of glypican 2 (GPC2) The CT3 antibody specific for tumor-associated exons has been isolated The complex structure of CT3 with GPC2 is visualized by electron microscopy CT3-derived CAR T cells regress neuroblastoma in mice Summary Targeting solid tumors must overcome several major obstacles, in particular, the identification of elusive tumor-specific antigens. Here, we devise a strategy to help identify tumor-specific epitopes.